Amivantamab was granted accelerated FDA approval in May 2021, thus making it the first approved therapy for patients with NSCLC with EGFR exon20 insertions after failure of platinum-containing chemotherapy. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.